BIOPHARMA
By
Is NVIDIA’s 2025 Healthcare AI Report the Tipping Point for 80% of Providers and Pharma to Redefine Efficiency and Innovation?
Key Highlights Healthcare Sees Rapid ROI with Generative AIAccording to NVIDIA’s 2025 State of AI in Healthcare and…
Could Everest Medicines’ AI-Powered mRNA Platform Signal a Turning Point for Cancer and Autoimmune Therapies in Asia?
Key Highlights Reimagining Cancer Vaccines with AI-Optimized PersonalizationAt the 2025 Everest Medicines R&D Day, the company showcased EVM16,…
Shift Bioscience Unveils AI Framework to Improve Gene Target Discovery for Rejuvenation Therapies
Key Highlights Deeper DiveCambridge-based Shift Bioscience is rethinking how AI models are evaluated for rejuvenation research. Their study,…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
